Sotatercept approved to treat adult patients with pulmonary arterial hypertension (PAH)

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved (27 December 2024) the medicine sotatercept (Winrevair) to treat pulmonary arterial hypertension (PAH).